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Recent studies suggest that, in addition to activation and hypersecretion of matrix components, ﬁbroblasts from
patients with systemic sclerosis (SSc) are relatively resistant to apoptosis. Transforming growth factor-b (TGF)-b is
strongly implicated in the pathogenesis of SSc and we and others have shown that TGF-b can activate Akt, a kinase
with potent anti-apoptotic effects. To determine whether Akt was activated in SSc, we quantiﬁed phospho-Akt
expression in skin ﬁbroblasts in vitro by western blot analysis and a functional kinase assay. In addition, the
relative proportion of ﬁbroblasts containing activated Akt in was quantiﬁed by immunohistochemistry on skin
sections in situ. Analysis of Akt phosphorylation of skin ﬁbroblasts in vitro suggested increased phosphorylation
of Akt, and evaluation of skin sections by immunohistochemistry revealed significantly higher percentages of
ﬁbroblasts that stained for phospho-Akt compared with controls (78%  14.0% vs 13%  9%, po0.001). In addition,
co-incident staining of phospho-Akt and a-smooth muscle actin was observed in some ﬁbroblasts. These ﬁndings
indicate that Akt is activated in situ in skin ﬁbroblasts from patients with SSc. Akt activation may contribute to
resistance to apoptosis, selection of disease-inducing ﬁbroblasts, and, possibly, myoﬁbroblasts.
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Systemic sclerosis (SSc) is a chronic autoimmune, vascular,
and fibrotic disease culminating in excessive accumulation
of extracellular matrix and fibrosis of the skin and internal
organs such as the heart, lungs, and intestinal tract (LeRoy
et al, 1988). Increased matrix synthesis by scleroderma fib-
roblasts is a phenotype maintained in vitro, suggesting that
the pathogenetic process of SSc favors the growth and/or
survival of subpopulations of pro-fibrotic fibroblast popula-
tions (Botstein et al, 1982; Goldring et al, 1990; Jelaska and
Korn, 2000). In vitro, SSc skin fibroblasts demonstrate in-
appropriate growth patterns such as persistent proliferation
in serum-free media associated with high expression of the
proto-oncogenes, c-myc (Trojanowska et al, 1988), and c-
myb (Piccinini et al, 1996). Furthermore, SSc skin fibroblasts
are resistant to Fas-mediated apoptosis that may, in part,
be a consequence of exposure to transforming growth fac-
tor-b (TGF)-b (Jelaska and Korn, 2000; Santiago et al, 2001).
One of the most potent pro-fibrotic stimuli to skin fibro-
blasts in vitro is TGF-b (Denton and Abraham, 2001). It has
been reported that TGF-b expression in lesional skin of SSc
is elevated (Gruschwitz et al, 1990; Kulozik et al, 1990;
Querfeld et al, 1999), although there are some conflicting
findings (Peltonen et al, 1990). Much of the evidence sug-
gesting that TGF-b plays a role in the pathogenesis of SSc
is based on in vitro studies of cells in culture (Cotton et al,
1998). TGF-b acts as a mitogen for skin fibroblasts, pre-
sumably through the induction of PDGF receptors (Ishikawa
et al, 1990). TGF-b induces a marked increase in collagen
as well as fibronectin synthesis (Ignotz and Massague,
1986; Roberts et al, 1986). Furthermore, TGF-b induces
transdifferentiation of fibroblasts into myofibroblasts (Des-
mouliere et al, 1993; Yokozeki et al, 1997; Gabbiani, 2003),
which synthesize elevated levels of collagen and TIMP-1
and show a much stronger effect in response to TGF-b (Kirk
and Kahn, 1995). TGF-b also stimulates extracellular matrix
assembly, including fibrillin assembly (Kissin et al, 2002),
which occurs in associations with myofibroblasts (Kissin
and Korn, 2002).
We have previously shown that TGF-b exerts its growth
and anti-apoptotic effects on fibroblasts, at least in part, by
activation of the phosphaditylinositol 3 (PI3) kinase/Akt
pathway (Kim et al, 2002). Others have shown similar find-
ings in other cell types (Shin et al, 2001; Vinals and Po-
uyssegur, 2001). Akt is a master regulator of growth control
that also influences the function of both the intrinsic
(mitochondrial) as well as the extrinsic (death receptor)
pathways of apoptosis, through the phosphorylation of
its substrates Bad (del Peso et al, 1997), caspase 9 (Datta
et al, 1999), forkhead transcription factors (Brunet et al,
1999), and IkB kinase (Ozes et al, 1999) resulting in their
activation or inhibition.
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We therefore hypothesized that inappropriate cell growth
and survival of skin fibroblasts in SSc were associated with
excessive activation of Akt and this phenomenon resulted
from stimulation by external factors, such as TGF-b. Here,
we report that Akt kinase is activated in SSc skin fibroblasts
in vitro and in vivo and that exposure of skin fibroblasts to
TGF-b-induced Akt activation. Taken together, we propose
that TGF-b signaling through Akt contributes to disease
pathogenesis.
Results
In vitro Akt activation in SSc skin ﬁbroblasts Since TGF-
b is associated with resistance of SSc fibroblasts to
apoptosis (Jelaska and Korn, 2000; Santiago et al, 2001),
and we and others have shown that TGF-b can activate
the anti-apoptotic kinase, Akt (Bakin et al, 2000; Kim et al,
2002), we performed pilot studies to address whether SSc
fibroblasts demonstrated higher Akt activation compared
with normal fibroblasts in vitro. Akt activation was deter-
mined by western blot analysis using anti-phospho-Akt (p-
Akt) antibody and the samples were ranked according to
the relative band density ratio of p-Akt to Akt. As shown in
Fig 1a, cultured SSc skin fibroblast cell strains showed
higher expression of p-Akt compared with normal skin fib-
roblast cell strains (9.8  0.8 vs 5.6  1.1, p¼0.012).
As an additional test of Akt activation in cultured SSc
fibroblasts in vitro, we used a method that quantifies func-
tional Akt enzymatic activity using glycogen synthase kin-
ase-3 (GSK-3) as the substrate. As shown in Fig 1b,
densitometric comparison of Akt activation from three SSc
(S4–S6) and four normal (N4–N7) skin fibroblast cell strains
showed a borderline significant difference (SSc, 75.2  10.7
vs control, 42.6  7.7, p¼ 0.05, Student’s t test). Taken to-
gether, these results suggest a higher baseline activation of
the Akt kinase in cultured SSc skin fibroblasts compared
with normal skin fibroblasts in vitro.
Activation of Akt in vivo Since the in vitro findings were
suggestive but not conclusive, we asked whether Akt was
activated in vivo by examining tissue sections obtained from
lesional skin. Control skin sections from inflammatory dis-
eases such as eczema and psoriasis as well as sections
from localized scleroderma (morphea) were used as con-
trols. As shown in representative hematoxylin & eosin
(H&E)-stained sections in Fig 2A, a much higher proportion
of SSc skin fibroblasts stained positive for p-Akt compared
with normal control skin sections (compare d and e) and
staining was specific as evidenced by lack of staining in
SSc fibroblasts with normal rabbit serum (g). As shown un-
der higher magnification (f), many of the p-Akt-positive cells
are spindle shaped, indicating their fibroblast origin. A
lymphohistocytic inflammatory infiltrate, especially promi-
nent around vessels, observed in the cases of SSc also
demonstrated p-Akt-positive staining. For purposes of
quantitation, only spindle-shaped nuclei in areas of dermal
sclerosis were used for analysis. On average, 210  12
fibroblasts were present and analyzed per sample. A sum-
mary of quantitation of p-Akt-positive fibroblasts is shown
in Fig 2B. The percentage of p-Akt-positive fibroblasts
was significantly higher in SSc patients versus controls
(78%  14.0% vs 13%  9%, po0.001).
Since activation of fibroblasts may lead to the production
of myofibroblasts in SSc (Kissin and Korn, 2002), we asked
whether p-Akt was co-expressed in skin myofibroblasts. In
three samples tested, sections were stained for p-Akt and
anti-a-smooth muscle actin (SMA). In two samples, p-Akt
was positive, but SMA was negative. A third sample stained
for both p-Akt and SMA (Fig 3). When the images were
merged, there was a clear overlap of the two stains indi-
cating co-expression.
Figure 1
Akt is activated in systemic sclerosis (SSc)
skin fibroblasts in vitro. (a) Total cell extracts of
cultured skin fibroblasts obtained from normal
(N, n¼7) and patients with scleroderma (SSc,
n¼6) were resolved by SDS-PAGE (50 mg pro-
tein per lane) and blotted to nitrocellulose.
Immunoblotting was performed with anti-phos-
pho-(p-Akt, Ser 473) or total (Akt) antibodies as
described in Materials and Methods. The relative
ratio of phospho-Akt to total Akt band density
was determined for normal and patients by
densitometry and ranked highest to lowest in
cumulative data from two separate experiments.
The mean (horizontal line)  SE (vertical line)
ranks for normal and SSc fibroblasts are shown
and are significantly different (p¼0.012). (b) Total
cell extracts from SSc- and control-cultured fib-
roblasts were obtained as in (a). Phospho-Akt
was immunoprecipitated from 500 mg of cell
lysate and the kinase reaction was performed
with glycogen synthase kinase-3 (GSK-3) fusion
protein as the substrate as described in Mate-
rials and Methods. Reaction products were re-
solved by SDS-PAGE and phospho-GSK-3
detected by immunoblotting. The results are
presented as percentage positive control (normal
skin fibroblasts stimulated with 10% fetal bovine
serum overnight). The blot is representative of
three individual experiments and the average  SE of these experiments are shown in the histogram. The difference between the mean kinase
activity in normals and SSc in these experiments was of borderline statistical significance (p¼0.05).
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SSc ﬁbroblasts and potential inducers of Akt activa-
tion TGF-b, IL-4, and CD40 have been implicated in the
induction of tissue fibrosis (Kaufman et al, 2001; Sime and
O’Reilly, 2001) and have been shown to induce Akt activa-
tion in certain cell types (Andjelic et al, 2000; Bakin et al,
2000; Arron et al, 2001; Kim et al, 2002). To determine
whether SSc fibroblasts were hypersensitive to TGF-b sig-
nal transduction through the PI3 kinase–Akt pathway, we
compared Akt activation between normal (n¼3) and SSc
(n¼ 3) fibroblasts following incubation with TGF-b in two
separate experiments. The ratios for each patient from the
two separate experiments were averaged and then com-
pared by Student’s t test. The mean  SE for normal
(1.7  0.1) and SSc (2.4  0.45) were not significantly dif-
ferent (p¼0.19). Although SSc fibroblasts responded to
TGF-b by activation of Akt (Fig 4) and were more responsive
to TGF-b than normal fibroblasts at 1, 2, 4, and 24 h, the
results were not statistically significantly different (not
shown).
Discussion
The pathology of SSc is tightly linked to the activation of
fibroblast populations (Botstein et al, 1982; Goldring et al,
1990). Recently, it has been reported that in addition to fib-
roblast activation, SSc skin fibroblasts are resistant to Fas-
mediated apoptosis and this resistance can be enhanced
by exposure of the cells to TGF-b (Jelaska and Korn, 2000;
Santiago et al, 2001). Despite the fact that similar observa-
tions have been made in rheumatoid arthritis synovial fib-
roblasts (Kawakami et al, 1996), the pathway through which
TGF-b exerts its protective effect from apoptosis remains
unknown. Significantly, the best-characterized pathway
of TGF-b signal transduction through Smad 2, 3, and 4
(Roberts and Derynck, 2001) is not known to directly
influence transcription of apoptotic regulators.
We recently showed that TGF-b-induced activation of
Akt in normal and RA synovial fibroblasts and that TGF-b
exerted its anti-apoptotic effect, in part, through the PI3
kinase/Akt pathway (Kim et al, 2002). Since TGF-b plays a
prominent role in the pathogenesis of SSc (Simms and
Korn, 2002), we examined whether Akt was activated in
skin fibroblasts of SSc patients. Here we show that both
by ;in vitro and, more significantly, in skin biopsies in situ,
Akt is phosphorylated in SSc skin fibroblasts. Although
Figure 2
Akt is activated in most systemic sclerosis (SSc) skin fibroblasts.
Skin biopsies were obtained from the following (abbreviation and
number studied in parentheses): Normal (N, 4); morphea (M, 4); other
skin diseases (OSD, psoriasis, 2 and eczema, 2); and SSc (9). Se-
quential sections were stained with hematoxylin & eosin (H&E) and p-
Akt (Ser473) by the immunoperoxidase technique described in Mate-
rials and Methods. Five fields were arbitrarily chosen and the total
number (H&E-stained sections) and p-Akt positive (peroxidase stained)
fibroblasts were counted per specimen at  20 magnification (1.070
mm2). (A) Representative H&E-stained sections (a–c) and p-Akt in situ
stained (d–f) sections from normal skin (a, d) and a case of SSc (b, c, e,
and f) are shown. At low power (  10), thickened, eosinophilic, closely
packed collagen bundles are seen by H&E in the dermis of the SSc
section (b). The corresponding immunoperoxidase stain for p-Akt
shows a markedly increased number of positive cells infiltrating the
dermis as compared with the normal dermis (e). At high magnification,
multiple stellate nuclei exhibit positive staining with p-Akt (f, arrows). In
(g), the SSc section was stained with normal rabbit serum, as a control.
(B) Summary of quantitation of the percentage of p-Akt-stained fibro-
blasts in SSc, and control samples as in (A). The percentage shown per
sample represents the percentage of p-Akt-positive fibroblasts out of
the total number of fibroblasts present in five fields at  20 magni-
fication in each sample. On average, 210  12 fibroblasts were present
and analyzed per sample.
Figure3
Akt co-localizes with a-smooth muscle actin (SMA) in systemic
sclerosis (SSc) fibroblasts. Sections from SSc skin biopsies were
stained with a-SMA and p-Akt. A Texas Red-labeled anti-mouse an-
tibody was used to visualize a-SMA (a), and an FITC-labeled anti-rabbit
antibody was used to visualize p-Akt (b). DAPI (blue) stains cell nuclei.
(c) Merged images of the immunolocalization of a-SMA and p-Akt are
shown. Scattered stellate nuclei in the dermis (arrows) demonstrate the
co-expression of a-SMA and p-Akt.
Figure4
Potential roles of transforming growth factor-b (TGF-b) in Akt ac-
tivation. Cultured skin fibroblast strains from three systemic sclerosis
(SSc) patients and three normal controls were serum starved overnight
and then incubated in the absence () or presence (þ ) of TGF-b1 (5 ng
per mL) for 1 h. Cell lysates were prepared and western blotting for p-
Akt and Akt was performed as in Fig 1. As detailed in Results, the
experiment was performed twice and the average pAkt/Akt ratios
compared between normal and SSc. No significant differences were
observed (p¼ 0.19). A representative blot showing results from two
normal (N7 and N8) and one SSc (S10) fibroblast extracts is shown.
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quantitative estimates of expression of phospho-Akt (P-Akt)
are not possible by immunohistochemistry, the numbers of
fibroblasts expressing p-Akt were strikingly increased in
SSc compared with both normal and disease controls. This
suggests that Akt phosphorylation is not a non-specific
manifestation of any type of skin inflammatory response.
The significance of the finding that Akt is activated in SSc
skin fibroblasts is severalfold. First, Akt is best known for its
anti-apoptotic effect that impacts both the death receptor
and mitochondrial pathways (Datta et al, 1999). Resistance
to apoptosis, which has been demonstrated experimentally
in SSc fibroblasts (Jelaska and Korn, 2000; Santiago et al,
2001), presumably contributes to accumulation of activated
fibroblasts in the skin promoting the accumulation of ex-
tracellular matrix. Second, Akt has been implicated in cell
transdifferentiation such as epithelial to mesenchymal tran-
sition (Bakin et al, 2000). Increased myofibroblasts are a key
finding in SSc (Jelaska and Korn, 2000) and they are as-
sociated with potent fibrogenic activity (Gabbiani, 1981;
Kirk et al, 1995). In a small sampling of skin biopsies from
SSc patients, we were able to demonstrate co-expression
of activated Akt and a-SMA, consistent with the notion that
Akt activation may play a role in the generation of these
myofibroblasts in disease states.
TGF-b has been implicated in the conversion of fibro-
blasts to myofibroblasts (Desmouliere et al, 1993; Yokozeki
et al, 1997), a transformation that occurs in concert with
induction of apoptosis resistance (Jelaska and Korn, 2000).
Although the pathway whereby this occurs is not known,
several observations lead us to speculate that this may oc-
cur through the PI3 kinase/Akt pathway. PI3 kinase plays
an important role in smooth muscle differentiation (Hayashi
et al, 1998) and myogenic signaling of PI3 kinase requires
Akt kinase (Jiang et al, 1999). Furthermore, apigenin, a
common dietary flavonoid, which inhibited Akt activation,
decreased expression of the myofibroblast phenotype (Ri-
cupero et al, 2001).
There are several potential explanations for activation of
Akt in SSc fibroblasts in situ. The most straightforward ex-
planation is that dermal fibroblasts are exposed to increased
amounts of bioactive TGF-b in lesional tissue. As discussed
above, however, there remains controversy regarding the
levels of active TGF-b at sites of fibrosis in patients with this
disease. An alternative explanation is that patients are hy-
persensitive to the effects of TGF-b. At a biochemical level,
this could be explained by failure to downmodulate TGF-b
signal transduction, as has recently been reported for TGF-b
signaling through the Smad pathway (Dong et al, 2002). The
TGF-b-associated antagonist LAP (latency-associated pep-
tide) has been shown to decrease skin fibrosis in a mouse
model of scleroderma (Zhang et al, 2003), suggesting that
regulation of TGF-b activity rather than absolute levels of
TGF-b contribute to the fibrosis in this disease. Many of the
genes reported as overexpressed in SSc fibroblasts are
known to be TGF-b-inducible genes including CTGF, colla-
gens, and fibronectin. Gene array studies support the con-
cept that there is overlap between TGF-b-induced genes
and those that characterize scleroderma fibroblasts (Ver-
recchia et al, 2001; Joseph H. Korn, unpublished observa-
tions). The increased proportion of myofibroblasts in SSc
may be another manifestation of this property.
Although we observed TGF-b to be a potent activator of
Akt in SSc-cultured fibroblasts, Akt activation in response to
TGF-b was not statistically significantly different between
SSc and normal controls. Although this result suggests
that there is no intrinsic abnormality of the Akt pathway in
SSc fibroblasts, cultured SSc skin fibroblasts are reported
to be less responsive to TGF-b in vitro (Kikuchi et al, 1992)
resulting from chronic exposure to TGF-b in vivo. More
detailed studies, possibly with fibroblasts from uninvolved
skin, will be needed to determine whether the PI3
kinase/Akt pathway, including the key phosphatases that
downmodulate p-Akt, PTEN, and SHIP (Datta et al, 1999),
function normally in this disease. In addition to TGF-b, other
cytokines, growth factors, or ligands such as CD40L could
potentially activate Akt and deserve further study.
A final point to note is that attenuation of PI3 kinase ac-
tivity by specific inhibitors decreased stabilization of a-1 (I)
collagen mRNA in human lung fibroblasts and that Akt ac-
tivation correlated with the change in a-1 (I) collagen mRNA
levels (Ricupero et al, 2001). Since SSc skin fibroblasts are
characterized by increased collagen production due, in
large part, to increased mRNA stability (Eckes et al, 1996),
the PI3 kinase/Akt pathway may be more directly involved in
SSc pathogenesis than hitherto thought. Whether selective
blockade of this pathway can be achieved without disrup-
tion of normal skin function remains a relevant avenue for
future research.
Materials and Methods
Materials Recombinant human TGF-b1 was purchased from R&D
System (Minneapolis, Minnesota). Antibodies to Akt, phospho-
specific Akt (Ser473), and phospho-Akt (Ser473) immunohisto-
chemistry-specific antibodies were purchased from Cell Signaling
Technology (Beverly, Massachusetts) and to anti-a-SMA from
Beckman Coulter (Fullerton, California). Horse anti-rabbit IgG an-
tibody was from Jackson ImmunoResearch Laboratories (West
Grove, Pennsylvania).
Fibroblast strains and cell culture A total of 15 SSc patients
(average age 50 y, 80% Caucasian and 80% female) were included
in this study. All SSc patients had diffuse disease and fulfilled the
American College of Rheumatology criteria for SSc (Masi et al,
1980). Skin biopsies were obtained from patients and control sub-
jects after informed consent in a protocol approved by the Insti-
tutional Review Board for Human Studies. Control biopsies of
lesional skin were obtained from patients with psoriasis, eczema,
and morphea. The tissue was fixed in formalin, embedded in par-
affin, and sections were stained with H&E. Fibroblasts were iso-
lated and cell strains cultured as described previously (Jelaska and
Korn, 2000). The cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM; Gibco Invitrogen, Grand Island, New
York) supplemented with 10% fetal calf serum (FCS, Gibco BRL,
Rockville, Maryland), 1% penicillin and streptomycin and L-gluta-
mine (Gibco BRL) in a humidified 5% CO2, 95% air incubator at
371C. Skin fibroblasts at third to seventh passages were used for
the experiments.
Western blot analysis Cells were seeded on six-well plates in
DMEM with 10% FCS overnight. The cultures were then starved
overnight in serum-free medium (DMEM with penicillin/streptomy-
cin and L-glutamine) to determine baseline Akt activation (Kim et al,
2002). In some experiments, cells were cultured in the presence
of TGF-b1 (5 ng per mL) for 1 h. Cells were washed twice in ice-
cold PBS and lysed with lysis buffer (50 mM Tris-HCl, pH 7.5, 1 mM
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EDTA, 1 mM EGTA, 0.5 mM Na3VO4, 0.1% 2-mercaptoethanol, 1%
Triton X-100, 50 mM NaF, 5 mM sodium pyrophosphate, 10 mM
sodium b-glycerophosphate, 0.1 mM PMSF, 1 mg per mL of apr-
otinin, leupeptin, and pepstatin, 137 mM NaCl, and 10% glycerol).
Protein concentration of cell lysates was determined by the Brad-
ford assay kit (Bio-Rad Laboratories, Hercules, California). Proteins
(50 mg) were resolved by SDS-PAGE (10%) and blotted to nitro-
cellulose membranes as described (Kim et al, 2002). Rabbit
anti-Akt (1:1000) or anti-phospho-specific (Ser 473) Akt (1:1000)
primary antibodies and horse anti-rabbit IgG (1:1000) secondary
antibody were used as probes and antibody binding was detected
by the enhanced chemiluminescent kit (Amersham Pharmacia
Biotech, Piscataway, New Jersey) as recommended by the man-
ufacturer. Band density was quantified by densitometry using the
ImageQuant program (Molecular Dynamics, Sunnyvale, California).
In vitro Akt kinase assay A functional assay for Akt phosphor-
ylation of the substrate GSK-3 was performed using a kit from New
England Biolabs (Beverly, Massachusetts) according to the man-
ufacturer’s recommendations. Briefly, 1  106 cells were starved
overnight in serum-free medium. Cells were lysed and phospho-
Akt immunoprecipitated from cell extracts (500 mg) with immobi-
lized phospho-specific Akt (Ser473) antibody. The bound enzyme
was incubated with the substrate, GSK-3 fusion protein, in the
presence of 200 mM ATP and kinase buffer (25 mM Tris-HCl, pH
7.5, 5 mM b-glycerophosphate, 2 mM DTT, 0.1 mMNa3VO4, 10 mM
MgCl2). The extent of GSK-3 phosphorylation was determined by
immunoblotting with anti-phospho-specific GSK-3 antibody and
quantified by densitometry. The band density obtained with the
test samples were compared with the positive control (normal
skin fibroblasts stimulated with 10% fetal bovine serum overnight)
and expressed as a percentage (test sample/positive control
 100).
In situ detection of Akt in skin biopsies Formalin-fixed, paraffin-
embedded skin samples were sectioned for immunohistochemis-
try. Six-micron sections were treated with 10 mM sodium citrate,
961C  15 min for antigen retrieval, stained with primary antibody
(phospho-Akt 1:25 for 2 h), followed by the appropriate secondary
biotinylated IgG, amplified with immunoperoxidase (Vectastain
ABC kit, Vector Laboratories, Burlingame, California), and visual-
ized with diaminobenzidine as chromagen. Sections were coun-
terstained with hematoxylin to visualize tissue morphology. For
immunofluorescence, 6 mm sections were treated with 10 mM so-
dium citrate, 961C  15 min, stained with anti-p-Akt (1:25 for 2 h),
followed by FITC-conjugated anti-rabbit antibody (1:400, Vector
Laboratories). Sections were then stained with anti-a-SMA anti-
body (1:2000 for 2 h), followed by Texas Red-conjugated anti-
mouse antibody (1:800, Vector Laboratories). DAPI, 50 mg per mL
(Sigma), was used to visualize cell nuclei. All antibody incubations
were performed at room temperature. Image acquisition was per-
formed using a Nikon Microphot-SA microscope equipped with a
CCD camera (Photometrics, Tuscon, Arizona). Data were collected
as single 1024 bit images, and RGB color merged using the soft-
ware program IPLab (Signal Analytics, Vienna, Virginia). Five fields
were arbitrarily chosen and counted per specimen at 200 (1.070
mm2). The total fibroblast numbers were counted on H&E-stained
sections and fibroblasts positive for peroxidase staining were
counted in the same fields. Results are expressed as a percentage
(phospho-Akt-positive fibroblasts/total fibroblasts in the field
 100).
Statistical analysis Values presented are mean  standard error
of mean (SEM). The statistical analyses were performed using
Student’s t test. Differences with p-values o0.05 were considered
statistically significant.
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